Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (
PATH
Pneumococcus
SIIPL
collaboration
low- and middle-income countries
pneumococcal conjugate vaccine
vaccine development
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
pubmed:
25
2
2021
medline:
14
10
2021
entrez:
24
2
2021
Statut:
ppublish
Résumé
Pneumococcal conjugate vaccines (PCVs) have proven to be the best way to prevent severe childhood pneumococcal disease but until recently have been difficult for many countries to afford sustainably. In 2008, the Serum Institute of India, Pvt. Ltd. and PATH entered into a collaboration, funded in part by the Bill & Melinda Gates Foundation, to respond to this problem by developing a PCV designed to be affordable, accessible, and protective against the pneumococcal serotypes causing the most morbidity and mortality in low- and middle-income countries. The resulting 10-valent PCV (
Identifiants
pubmed: 33625961
doi: 10.1080/21645515.2021.1874219
pmc: PMC8475595
doi:
Substances chimiques
10-valent pneumococcal conjugate vaccine
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2670-2677Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
PLoS Med. 2014 Jun 03;11(6):e1001657
pubmed: 24892763
Vaccine. 2020 Jan 10;38(2):399-410
pubmed: 31843266
PLoS Med. 2010 Oct 05;7(10):
pubmed: 20957191
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Lancet. 2013 Jan 19;381(9862):214-22
pubmed: 23158882
Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46
pubmed: 15794968
Lancet. 2019 May 25;393(10186):2146-2154
pubmed: 31000194
Lancet Infect Dis. 2021 Jun;21(6):834-846
pubmed: 33516293
Lancet Glob Health. 2019 Mar;7(3):e337-e346
pubmed: 30784634